Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 186,549 shares, an increase of 220.0% from the February 26th total of 58,304 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average trading volume of 710,018 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On Calidi Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics during the 4th quarter valued at $25,000. Warberg Asset Management LLC bought a new stake in Calidi Biotherapeutics in the third quarter worth $28,000. Geode Capital Management LLC boosted its position in Calidi Biotherapeutics by 41.7% during the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after buying an additional 12,334 shares during the period. Finally, DRW Securities LLC purchased a new stake in Calidi Biotherapeutics during the fourth quarter valued at about $173,000. 12.53% of the stock is owned by hedge funds and other institutional investors.

Calidi Biotherapeutics Stock Performance

Shares of Calidi Biotherapeutics stock traded down $0.01 during trading hours on Friday, reaching $0.27. The company had a trading volume of 185,916 shares, compared to its average volume of 221,831. Calidi Biotherapeutics has a one year low of $0.26 and a one year high of $19.20. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12. The business has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $1.19.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.